Home
/
Conditions
/ Atrial Fibrillation
Cardiovascular Health
Schedule a Consultation
Atrial Fibrillation
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting an estimated 6 million Americans. Conventional cardiology manages the rhythm disturbance with rate control, anticoagulation, and ablation. Functional medicine asks what is producing the atrial electrical instability in the first place: systemic inflammation, insulin resistance, autonomic imbalance, electrolyte depletion, thyroid dysfunction, oxidative stress, and sleep-disordered breathing are among the most commonly identified and most treatable upstream drivers. At The Lamkin Clinic, we evaluate and treat the metabolic substrate that sustains the arrhythmia.
Cardiovascular HealthRoot Cause MedicineModifiable Drivers
~6MAmericans currently have atrial fibrillation
5xincreased risk of stroke compared to those without AFib
Modifiablewhen the inflammatory, metabolic, and autonomic drivers are identified
← Back to Conditions
Condition: Atrial Fibrillation | Category: Cardiovascular Health | Reviewed by: Brian Lamkin, DO
What Is Atrial Fibrillation?
Atrial fibrillation (AFib) is a cardiac arrhythmia characterized by chaotic, disorganized electrical activity in the atria that replaces the normal sinus rhythm with rapid, irregular atrial contractions. This produces an irregularly irregular ventricular response, reduced cardiac output, blood stasis in the atrial appendage (creating thromboembolic stroke risk), and the constellation of symptoms including palpitations, fatigue, exercise intolerance, and cognitive impairment that define the patient experience.
Conventional cardiology classifies AFib by pattern (paroxysmal, persistent, or permanent) and manages it with rate control, rhythm control, anticoagulation, and catheter ablation. This approach addresses the electrical event without investigating the metabolic substrate that makes it possible. The atrial tissue does not become electrically unstable spontaneously. It is remodeled by inflammation, fibrosis, oxidative stress, autonomic imbalance, and metabolic dysfunction into a substrate that sustains the arrhythmia. Functional medicine identifies and treats these upstream drivers to modify the substrate itself.
Key principle: AFib is not just an electrical problem. It is an inflammatory, metabolic, and autonomic problem that expresses itself electrically. Elevated hs-CRP is independently associated with AFib incidence, recurrence after cardioversion, and ablation failure. Treating the inflammation, the insulin resistance, the magnesium depletion, and the sleep apnea changes the atrial substrate in ways that rate control and ablation alone cannot.
Why It Matters
Clinical Consequences
- Five-fold increased risk of stroke from thrombus formation in the fibrillating left atrial appendage
- Heart failure risk doubles because the loss of atrial contribution to ventricular filling reduces cardiac output by 15 to 25 percent
- Cognitive decline accelerates from both subclinical cerebral emboli and reduced cardiac output producing chronic cerebral hypoperfusion
- Mortality is increased 1.5 to 2 fold across all age groups, driven by stroke, heart failure, and the metabolic burden that produced the arrhythmia
Why Standard Cardiology Falls Short
- Rate and rhythm control address the electrical event without modifying the atrial substrate that sustains it; recurrence rates after cardioversion exceed 50 percent at one year
- Catheter ablation success rates decline in patients with persistent inflammation, untreated sleep apnea, and ongoing metabolic dysfunction
- Inflammatory markers, insulin status, and magnesium levels are not standard components of the AFib evaluation despite strong evidence linking each to arrhythmia burden
- Sleep apnea is present in approximately 50 percent of AFib patients and doubles recurrence rates, yet screening is not systematic in standard cardiology practice
Common Symptoms
Cardiac
- Heart palpitations: awareness of rapid, irregular heartbeat
- Chest discomfort or pressure during episodes
- Shortness of breath with exertion or at rest during AFib
- Reduced exercise tolerance from diminished cardiac output
Neurological
- Lightheadedness and dizziness from reduced cerebral perfusion
- Brain fog and cognitive difficulty during and between episodes
- Fatigue disproportionate to activity level
- Anxiety from autonomic adrenaline surges accompanying arrhythmia
Systemic
- Sleep disruption from nocturnal AFib episodes
- Polyuria during episodes from atrial natriuretic peptide release
- Asymptomatic episodes detected only on monitoring (common and still carry stroke risk)
- Progressive exercise limitation as AFib burden increases
Root Causes: A Functional Medicine Perspective
The conventional cardiology model treats AFib as a primary electrical disorder. The functional medicine model recognizes it as a secondary consequence of atrial substrate remodeling driven by identifiable and modifiable upstream factors.
Systemic Inflammation and Atrial Fibrosis
Elevated hs-CRP and pro-inflammatory cytokines produce fibroblast activation in atrial tissue, creating fibrosis that disrupts normal electrical conduction pathways and provides the structural substrate for reentrant circuits. Chronic inflammation from visceral adiposity, gut dysbiosis, periodontal disease, and metabolic dysfunction is the most consistently identified modifiable risk factor for AFib development and recurrence.
Insulin Resistance and Metabolic Syndrome
Insulin resistance promotes AFib through multiple converging pathways: it drives systemic inflammation that fibroses atrial tissue, increases epicardial adipose tissue that directly contacts and inflames the atrial myocardium, worsens oxidative stress that damages ion channels, and produces the metabolic syndrome cluster (hypertension, dyslipidemia, visceral obesity) that independently increases arrhythmia risk. Elevated fasting insulin and HbA1c identify this driver.
Electrolyte Depletion
Magnesium is a natural calcium channel blocker that stabilizes atrial myocyte membrane potential. RBC magnesium depletion (not detectable on serum magnesium, which remains normal until intracellular stores are severely depleted) is prevalent in AFib patients and independently associated with increased arrhythmia burden. Potassium depletion compounds the electrophysiological instability. Diuretic use, common in AFib patients with hypertension, worsens both magnesium and potassium depletion.
Thyroid Dysfunction and Sleep Apnea
Both hyperthyroidism and hypothyroidism increase AFib risk through distinct mechanisms. Hyperthyroidism increases atrial automaticity; hypothyroidism promotes atrial fibrosis through inflammatory and metabolic pathways. Thyroid evaluation is essential in every AFib patient. Obstructive sleep apnea, present in approximately 50 percent of AFib patients, produces intermittent hypoxia and acute autonomic surges that trigger atrial ectopy. Untreated sleep apnea doubles AFib recurrence after cardioversion and ablation.
Conventional vs Functional Medicine Approach
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Assessment | ECG, Holter, echocardiogram; CHA2DS2-VASc stroke risk scoring | All standard cardiac assessment plus hs-CRP, fasting insulin, RBC magnesium, thyroid panel, sleep study, and metabolic evaluation |
| Treatment | Rate control (beta-blockers, calcium channel blockers), rhythm control (antiarrhythmics, cardioversion), ablation, anticoagulation | Substrate modification: anti-inflammatory intervention, insulin sensitization, magnesium repletion, sleep apnea treatment, thyroid optimization alongside indicated conventional management |
| Root cause | Not systematically investigated; lifestyle advice in general terms | Inflammation, metabolic syndrome, electrolyte depletion, thyroid dysfunction, and sleep apnea evaluated as independent treatable drivers |
| Goal | Rate or rhythm control; stroke prevention | Atrial substrate modification to reduce arrhythmia burden through resolution of upstream drivers |
Key Labs to Evaluate
AFib evaluation through a functional medicine lens requires markers that identify the inflammatory, metabolic, and electrolyte drivers sustaining the atrial substrate.
hs-CRPInflammatory burden. Elevated hs-CRP independently predicts AFib incidence and recurrence.
→HbA1cGlycemic control. Metabolic syndrome and insulin resistance drive atrial remodeling.
→Fasting InsulinThe earliest metabolic driver of the inflammatory and oxidative pathways sustaining AFib.
→CortisolAutonomic and stress axis status. Cortisol dysregulation worsens autonomic AFib triggers.
→RBC MagnesiumIntracellular magnesium status. Depletion destabilizes atrial myocyte membrane potential.
→How to Interpret These Labs Together
Elevated hs-CRP with elevated fasting insulin and low RBC magnesium is the inflammatory-metabolic-electrolyte AFib triad: inflammation is fibrosis-remodeling the atria, insulin resistance is driving the inflammation and oxidative stress, and magnesium depletion is destabilizing the electrical substrate. Addressing all three simultaneously produces the most significant substrate modification.
Elevated HbA1c with elevated hs-CRP and untreated sleep apnea identifies the metabolic-inflammatory-sleep triad that produces the highest AFib recurrence rates. Sleep apnea treatment alone reduces AFib recurrence by up to 40 percent in clinical studies. Combined with metabolic optimization and anti-inflammatory intervention, the cumulative substrate modification is substantial.
Low RBC magnesium with normal serum magnesium is the most commonly missed electrolyte finding in AFib. Serum magnesium remains normal until intracellular stores are severely depleted. RBC magnesium is the clinically relevant measurement that identifies the majority of magnesium-depleted AFib patients who are missed by standard serum testing.
Common Patterns Seen in Patients
- The AFib patient with recurrence after ablation: Successful pulmonary vein isolation initially, but AFib recurred within 8 months. hs-CRP 4.2, fasting insulin 18, RBC magnesium low, sleep study positive for moderate obstructive sleep apnea. The ablation addressed the electrical trigger, but the inflammatory and metabolic substrate that produced the trigger was never modified. CPAP, anti-inflammatory intervention, insulin sensitization, and magnesium repletion reduced AFib burden by 80 percent over 6 months.
- The paroxysmal AFib triggered by stress and alcohol: Episodes correlating with occupational stress and weekend alcohol consumption. Cortisol pattern flat, RBC magnesium depleted, hs-CRP 2.8. Autonomic triggers (stress-driven catecholamine surges) operating on an electrolyte-depleted, inflamed atrial substrate. Magnesium repletion, cortisol management, alcohol elimination, and anti-inflammatory support reduced episode frequency from weekly to one episode in three months.
- The AFib patient on three cardiac medications with persistent symptoms: On metoprolol, flecainide, and apixaban. Still experiencing weekly episodes with fatigue between events. Fasting insulin 22, HbA1c 6.1 (prediabetic), sleep apnea undiagnosed. The metabolic substrate sustaining the arrhythmia was never evaluated. Metabolic intervention and CPAP reduced AFib burden more effectively than the third cardiac medication that had been added.
- Lone AFib in a young endurance athlete: No metabolic risk factors. High-intensity endurance training producing chronic vagal remodeling and atrial dilatation. RBC magnesium depleted from exercise-induced magnesium loss. Autonomic-driven paroxysmal AFib. Training modification, magnesium repletion, and omega-3 supplementation reduced episode frequency without requiring antiarrhythmic medication.
Treatment and Optimization Strategy
Substrate Modification
The functional medicine approach to AFib does not replace conventional cardiac management when indicated. It adds a layer of upstream driver treatment that modifies the atrial substrate, reduces arrhythmia burden, improves response to conventional interventions, and addresses the cardiovascular risk that produced the arrhythmia in the first place.
Anti-Inflammatory and Metabolic
- Omega-3 fatty acids (3 to 4g EPA+DHA daily) for atrial anti-inflammatory and antiarrhythmic effect; membrane-stabilizing properties independent of anti-inflammatory action
- CoQ10 (200 to 400mg daily as ubiquinol) for mitochondrial support and antioxidant protection of atrial myocyte ion channels
- Insulin sensitization through low-glycemic nutrition, time-restricted eating, and berberine or metformin to reduce the metabolic-inflammatory driver
- Curcumin (1000mg bioavailable form) for IL-6 and TNF-alpha reduction to slow atrial fibrotic remodeling
Electrolyte, Thyroid, and Sleep
- Magnesium glycinate or taurate (400 to 800mg daily) targeting RBC magnesium normalization; the single most impactful electrolyte intervention for AFib
- Potassium optimization through dietary increase and monitoring, particularly in patients on diuretics
- Thyroid optimization with full panel evaluation; both hyper and hypothyroid states independently increase AFib risk
- Sleep apnea screening and treatment: CPAP for moderate to severe OSA reduces AFib recurrence by up to 40 percent and is one of the highest-leverage single interventions available
What Most Doctors Miss
- Inflammation is not measured: hs-CRP is the strongest modifiable predictor of AFib incidence and recurrence, yet it is not part of the standard AFib evaluation in most cardiology practices
- RBC magnesium is not tested: serum magnesium misses the majority of magnesium-depleted patients. RBC magnesium identifies intracellular depletion that directly affects atrial electrophysiology. Magnesium repletion is one of the safest and most effective interventions available for AFib burden reduction.
- Insulin resistance is not evaluated: metabolic syndrome is an independent driver of atrial remodeling, yet fasting insulin and HOMA-IR are not part of standard AFib workup despite strong mechanistic and epidemiological evidence
- Sleep apnea screening is not systematic: present in approximately 50 percent of AFib patients and doubles recurrence rates, yet screening is frequently omitted or delayed in standard cardiology care
When to Seek Medical Care
If you experience heart palpitations, an irregular heartbeat, unexplained fatigue, exercise intolerance, lightheadedness, or episodes of shortness of breath, cardiac evaluation for arrhythmia is warranted. If you have established AFib with recurrence despite medication or ablation, or if your AFib coexists with metabolic syndrome, obesity, or sleep disruption, a comprehensive evaluation of the upstream drivers is indicated.
At The Lamkin Clinic, AFib evaluation includes standard cardiac assessment plus hs-CRP, fasting insulin, HbA1c, RBC magnesium, full thyroid panel, cortisol, and sleep apnea screening, reviewed as an integrated cardiovascular and metabolic profile.
Recommended Testing
AFib evaluation through a functional medicine lens requires testing that identifies the inflammatory, metabolic, and electrolyte drivers sustaining the arrhythmia substrate.
Foundational Labs
- hs-CRP
- RBC Magnesium
- TSH, Free T3, Free T4
- Fasting Insulin
Advanced Assessment
- HbA1c
- HOMA-IR
- Cortisol (AM)
- Omega-3 Index
- Sleep Study (polysomnography)
Not sure which testing applies to you?
Explore All Testing Options →Frequently Asked Questions
Can atrial fibrillation be caused by inflammation?
Yes. Systemic inflammation is one of the most consistently identified upstream drivers of AFib. Elevated hs-CRP is independently associated with AFib incidence, recurrence after cardioversion, and failure of ablation procedures. Inflammatory cytokines produce atrial fibrosis, electrical remodeling, and oxidative stress that create the substrate for sustained arrhythmia.
Does magnesium help atrial fibrillation?
Magnesium is a critical electrolyte for cardiac rhythm stability. It functions as a natural calcium channel blocker and maintains the resting membrane potential of atrial myocytes. Magnesium deficiency is prevalent in AFib patients and independently associated with increased arrhythmia burden. RBC magnesium (not serum magnesium) is the clinically relevant measurement.
What is the connection between sleep apnea and AFib?
Obstructive sleep apnea is present in approximately 50 percent of AFib patients. Each apneic episode produces intermittent hypoxia, sympathetic nervous system surges, and intrathoracic pressure changes that trigger atrial ectopy and sustained fibrillation. Untreated sleep apnea doubles the rate of AFib recurrence after cardioversion and ablation.
Can insulin resistance cause AFib?
Yes. Insulin resistance promotes AFib through multiple pathways: it drives systemic inflammation that produces atrial fibrosis, increases epicardial fat that directly inflames atrial tissue, worsens oxidative stress, and produces the metabolic syndrome cluster that independently increases arrhythmia risk.
Is AFib reversible?
Paroxysmal AFib is the most responsive to upstream driver intervention. When the inflammatory, metabolic, electrolyte, thyroid, and sleep drivers are identified and treated, many patients experience significant reduction in episode frequency and duration. Persistent AFib with established atrial remodeling is more difficult to reverse but still benefits from metabolic substrate modification alongside conventional rhythm management.
How The Lamkin Clinic Approaches Atrial Fibrillation
Clinical Perspective
When I evaluate an AFib patient, I am not looking at the arrhythmia. I am looking at what produced it. In nearly every case, I find elevated inflammatory markers, insulin resistance, depleted RBC magnesium, undiagnosed sleep apnea, or some combination of these. These are the drivers that remodeled the atrial tissue into a substrate that sustains the arrhythmia. Rate control and ablation address the electrical event; substrate modification addresses why the electrical event keeps happening. The patients who do best are the ones where we treat both.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
At The Lamkin Clinic, AFib evaluation includes standard cardiac assessment plus comprehensive metabolic and inflammatory testing: hs-CRP, fasting insulin, HbA1c, RBC magnesium, full thyroid panel, cortisol, and sleep apnea screening. Treatment is built as a substrate modification protocol: anti-inflammatory intervention, metabolic optimization, electrolyte repletion, sleep apnea treatment, and thyroid optimization, coordinated alongside indicated conventional cardiac management.
Related Conditions
Cardiovascular Disease RiskAFib shares the inflammatory and metabolic drivers that produce broader cardiovascular risk
→Metabolic SyndromeThe metabolic cluster that independently increases AFib risk and recurrence
→Thyroid DysfunctionBoth hyper and hypothyroid states independently increase AFib risk
→Insulin ResistanceMetabolic driver of atrial fibrosis, oxidative stress, and epicardial fat accumulation
→Chronic InflammationThe primary modifiable risk factor for atrial remodeling and AFib substrate
→Adrenal DysfunctionCortisol and catecholamine dysregulation as autonomic AFib triggers
→Related Symptoms
Chronic FatigueReduced cardiac output and metabolic burden producing persistent low energy
→Brain FogCerebral hypoperfusion from reduced cardiac output impairing cognition
→Anxiety PhysiologyAutonomic catecholamine surges during AFib episodes producing anxiety
→Sleep DisturbanceSleep apnea and nocturnal arrhythmia disrupting restorative sleep
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Atrial fibrillation has identifiable metabolic, inflammatory, and electrolyte drivers.
The Lamkin Clinic evaluates AFib with hs-CRP, RBC magnesium, fasting insulin, thyroid, and comprehensive cardiovascular assessment. Schedule a consultation for a root-cause substrate evaluation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.